Perrigo CEO to Present at UBS Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PRGO?
Source: PRnewswire
- Conference Schedule: Perrigo's CEO Patrick Lockwood-Taylor is set to present at the UBS Global Consumer and Retail Conference on March 11, 2026, at 11:00 AM EDT, highlighting the company's leadership in consumer health.
- Webcast Access: Interested parties can access the conference webcast via Perrigo's official website, ensuring that investors and the public can stay updated on the company's latest developments and strategic direction.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience, focusing on high-quality health and wellness solutions primarily for North America and Europe, emphasizing accessibility in over-the-counter self-care products.
- Business Model: Perrigo's unique business model leverages cash-generative private label offerings to fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, showcasing its competitive advantage in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 11.390
Low
18.00
Averages
20.33
High
23.00
Current: 11.390
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo CEO to Present at UBS Conference
- Conference Schedule: Perrigo's CEO Patrick Lockwood-Taylor is set to present at the UBS Global Consumer and Retail Conference on March 11, 2026, at 11:00 AM EDT, highlighting the company's leadership in consumer health.
- Webcast Access: Interested parties can access the conference webcast via Perrigo's official website, ensuring that investors and the public can stay updated on the company's latest developments and strategic direction.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience, focusing on high-quality health and wellness solutions primarily for North America and Europe, emphasizing accessibility in over-the-counter self-care products.
- Business Model: Perrigo's unique business model leverages cash-generative private label offerings to fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, showcasing its competitive advantage in the market.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
- Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
- Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
See More
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
See More
Perrigo Company Q4 2025 Earnings Call Insights
- Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
- Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
- Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
- Cautious Future Outlook: Management anticipates 2026 to be a
See More
PERRIGO STOCK DROPS 7.4% FOLLOWING Q4 PROFIT DISAPPOINTMENT
- Company Performance: Perrigo shares fell by 7.4% following the announcement of their fourth-quarter results.
- Profit Estimates: The decline in share value was attributed to missing profit estimates for the quarter.
See More
Perrigo Issues 2026 Financial Guidance Amid Losses
- 2026 Financial Outlook: Perrigo projects adjusted earnings per share for fiscal 2026 to be between $2.00 and $2.30, despite an anticipated total net sales decline of 5.5% to 1.5%, indicating significant market challenges and the urgency of strategic adjustments.
- Core Business Focus: The company sets its adjusted earnings per share for core operations at $2.25 to $2.55, with core net sales expected to change between a decline of 3.0% and growth of 1.0%, demonstrating Perrigo's prioritization of resource allocation to navigate market fluctuations.
- Operational Enhancement Program: Perrigo has launched a two-year enterprise-wide operational enhancement program, expecting to reduce approximately 7% of its workforce to improve supply chain and distribution efficiency, thereby strengthening its competitive position in the market.
- Widening Financial Losses: The company reported a net loss of $1.42 billion for the fourth quarter, translating to a loss of $10.22 per share, significantly up from a loss of $44.5 million or $0.32 per share in the prior year, primarily due to goodwill impairment charges, reflecting the financial pressures currently faced by the company.
See More
Perrigo CEO to Present at UBS Conference
- Conference Schedule: Perrigo's CEO Patrick Lockwood-Taylor is set to present at the UBS Global Consumer and Retail Conference on March 11, 2026, at 11:00 AM EDT, highlighting the company's leadership in consumer health.
- Webcast Access: Interested parties can access the conference webcast via Perrigo's official website, ensuring that investors and the public can stay updated on the company's latest developments and strategic direction.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience, focusing on high-quality health and wellness solutions primarily for North America and Europe, emphasizing accessibility in over-the-counter self-care products.
- Business Model: Perrigo's unique business model leverages cash-generative private label offerings to fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, showcasing its competitive advantage in the market.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
- Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
- Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
See More
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
See More
Perrigo Company Q4 2025 Earnings Call Insights
- Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
- Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
- Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
- Cautious Future Outlook: Management anticipates 2026 to be a
See More
PERRIGO STOCK DROPS 7.4% FOLLOWING Q4 PROFIT DISAPPOINTMENT
- Company Performance: Perrigo shares fell by 7.4% following the announcement of their fourth-quarter results.
- Profit Estimates: The decline in share value was attributed to missing profit estimates for the quarter.
See More
Perrigo Issues 2026 Financial Guidance Amid Losses
- 2026 Financial Outlook: Perrigo projects adjusted earnings per share for fiscal 2026 to be between $2.00 and $2.30, despite an anticipated total net sales decline of 5.5% to 1.5%, indicating significant market challenges and the urgency of strategic adjustments.
- Core Business Focus: The company sets its adjusted earnings per share for core operations at $2.25 to $2.55, with core net sales expected to change between a decline of 3.0% and growth of 1.0%, demonstrating Perrigo's prioritization of resource allocation to navigate market fluctuations.
- Operational Enhancement Program: Perrigo has launched a two-year enterprise-wide operational enhancement program, expecting to reduce approximately 7% of its workforce to improve supply chain and distribution efficiency, thereby strengthening its competitive position in the market.
- Widening Financial Losses: The company reported a net loss of $1.42 billion for the fourth quarter, translating to a loss of $10.22 per share, significantly up from a loss of $44.5 million or $0.32 per share in the prior year, primarily due to goodwill impairment charges, reflecting the financial pressures currently faced by the company.
See More
